載入中
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
前收盤價
US$21.84
−US$0.75 · -3.32%
盤前
US$21.79
−US$0.05 · -0.23%
10月13日 上午8:23 ET
盤中時間採用ET。市場資料可能有所延遲。
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
日內區間
目前US$21.84
52週區間
目前US$21.84
盤中時間採用ET。市場資料可能有所延遲。
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
日內區間
目前US$21.84
52週區間
目前US$21.84
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1609.8萬 USD | 2711.9萬 USD | 1584.3萬 USD | 1.06億 USD | 5.24億 USD |
| 銷貨成本 | 168.6萬 USD | 1832.7萬 USD | 1362.8萬 USD | 334.3萬 USD | 2497.6萬 USD |
| 毛利 | 1441.2萬 USD | 879.2萬 USD | 221.5萬 USD | 1.03億 USD | 4.99億 USD |
| 研究與開發 | 1.41億 USD | 1.44億 USD | 2.15億 USD | 1.98億 USD | 1.44億 USD |
| 銷售、一般及管理費用 | 6533.7萬 USD | 5068.2萬 USD | 7307.9萬 USD | 5469.8萬 USD | 5629萬 USD |
| 營業費用 | 2.02億 USD | 1.93億 USD | 2.85億 USD | 2.46億 USD | 1.88億 USD |
| 利息收入 | 1696.7萬 USD | 2141.5萬 USD | 1956.2萬 USD | 60.9萬 USD | 16.2萬 USD |
| 利息支出 | 6199.4萬 USD | 6374.1萬 USD | 4155.7萬 USD | 1170.4萬 USD | 747.4萬 USD |
| 折舊和攤銷 | 1475.9萬 USD | 1264.1萬 USD | 1190萬 USD | 853.7萬 USD | 729.9萬 USD |
| 營業利益 | −1.88億 USD | −1.84億 USD | −2.83億 USD | −1.43億 USD | 3.11億 USD |
| 淨利 | −1.99億 USD | −2.4億 USD | −3.08億 USD | −1.27億 USD | 3.3億 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$52.60
上漲空間 140.84%報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI4518.03萬0.46%103.03億 USD0.35%US$151.4-1.54%
Vanguard Extended Market ETFVXF3847.48萬0.04%954億 USD0.05%US$233.52-0.63%
iShares Biotechnology ETFIBB1130.67萬0.10%108.2億 USD0.44%US$204.26-1.08%
Schwab U.S. Small-Cap ETFSCHA798.1萬0.04%217.13億 USD0.03%US$32.66-0.40%
Vanguard Health Care ETFVHT766.19萬0.03%220億 USD0.09%US$320.67+0.52%
Invesco Dorsey Wright Healthcare Momentum ETFPTH298.62萬1.04%2.87億 USD0.74%US$58.3797-0.65%
Direxion Daily S&P Biotech Bull 3X SharesLABU219.03萬0.34%6.49億 USD0.96%US$231.99-4.57%
iShares Core S&P Total U.S. Stock Market ETFITOT201.83萬0.00%980.88億 USD0.03%US$169.43-0.14%State Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTInvesco Dorsey Wright Healthcare Momentum ETFPTHDirexion Daily S&P Biotech Bull 3X SharesLABUiShares Core S&P Total U.S. Stock Market ETFITOTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
